New drugs on the market are increasingly expensive and directed to increasingly smaller subsets of patients. Combined with the ageing population and increasing overall costs of health care, the issue of the price of treatment versus its benefits is becoming increasingly important. The effectiveness of treatment, expressed in concepts like Real World Data (RWD) and Real World Evidence (RWE), is the topic of at least half of the articles written by the pharmaceutical and health care sector.